Breast cancer survival rates are correlated with a number of factors, including stage of cancer, indicating if it has spread; type of breast cancer; grade of cancer; HER2 status; hormone receptor status; and growth rate of cancer cells
The one-size-fits-all approach to early stage breast cancer creates a paradox: Millions of dollars are spent on unnecessary surgeries and radiation to treat women with low-risk ‘in situ’ lesions, an estimated 85% of which would never progress to invasive cancers. Meanwhile, the standard conservative treatment is insufficient for many early-stage tumors that have progressed past the in situ stage and fails to prevent their spread to distant sites in the body. Now Whitehead Institute researchers have identified SMARCE1, a gene overexpressed in the subset of early-stage cancers that are likely to become aggressively invasive – making it possible for the first time to distinguish poorly invasive tumors from those that will likely spread and metastasize. With such a biomarker, doctors could better tailor therapies designed to match the behavior of each patient’s cancer.
The way that a doctor treats ER-positive breast cancer depends on many factors, including the stage of cancer, how much it has spread, and the source of cancer. If the cancer is ER- or PR-positive, hormone therapy will almost certainly be included in the treatment plan for the patient.
A study of nearly 280,000 women in the United States has found that living in areas with a high level of fine particles from air pollution may increase a woman’s chance of having dense breasts – a well-established risk factor for breast cancer – according to a new study published in the open access journal Breast Cancer Research.
In the mouse study, researchers from the NYU Langone Medical Center and Perlmutter Cancer Center in New York showed that the targeted agents known as mTOR inhibitors block chemotherapy-induced damage to the ovaries that causes infertility.
Once you have cancer, it will follow you around like toilet paper stuck to your flip-flop: You’re constantly reminded of it, and you’re constantly afraid of it coming back. The anxiety after cancer treatment ends is sometimes crippling. It’s like having the Grim Reaper as your neighbor.
Although these are all small studies, together they point to imbalances or deficits in neurotransmitter activity as risk factors for cognitive impairment after cancer treatment, a conclusion that could have a variety of treatment implications. For example, research shows that in animal models, the antidepressant fluoxetine can prevent or improve memory problems associated with the chemotherapy treatment 5-FU.
Hormone receptor-positive breast cancers have many hormone receptors. When breast cancer develops, the tumor cells become overly sensitive to estrogen. When estrogen activates the estrogen receptor, it turns on a panel of genes that tell the cells to keep dividing, driving tumor growth. However, when breast cancer cells have working progesterone receptors, and there is sufficient progesterone available, progesterone will slow down estrogen fueled growth and division of these cells.
“Since these large databases play an important role in making healthcare policy, it’s important to appreciate the significant differences in racial and socioeconomic disparities in immediate breast reconstruction,” senior author Samuel J. Lin, MD, MBA, of Harvard Medical School, and a member of the American Society of Plastic Surgeons, said in a press release.
This article covers the work of Royal Rife, a scientist who could well have been at least 80 years ahead of his time. Not only did he invent one of the most powerful microscopes ever seen, he used it to identify foreign matter, which he called a ´virus´, at the heart of every cancer. He then went on to work out the energetic frequency of each of the different ´viruses´ he found and even build a ´Rife Machine´, or colloquially a zapper, which could adjust electrofrequency and kill off that particular ´virus´ leaving healthy cells untouched. He was ridiculed, attacked and his work stopped. He died a pauper. Only now are scientists once again thinking there might be an infection contributing to every cancer, as Big Pharma contemplates the profits involved in developing a myriad of vaccines.
A colourful Mediterranean Diet, or a Rainbow Diet, can reduce the risk of post-menopausal breast cancer by 40 per cent, according to research by the World Cancer Research Fund. It was particularly effective at reducing non-estrogen positive breast cancers (ER-) like Triple Negative Breast Cancer and HER2+ Breast Cancer, which have been increasing and now account for a third of all newly diagnosed breast cancers.
Replacing BPA in common products allows manufacturers to claim their goods are BPA-free. It doesn’t mean that the plastics, receipts or paper currency containing replacement compounds are safe. Bisphenol S, or BPS, is one of the most widely used replacements. Testing in breast cancer cells shows, however, that BPS also mimics estrogen and is an endocrine disruptor.
Scientists at Duke University have found that this endocrine-disrupting compound can make inflammatory breast cancer cells resist treatment. When these cancer cells are treated with bisphenol A in the laboratory, they generate more of the signaling molecules called epidermal growth factor receptors. A low dose of BPA doubled the amount of EGFR on cell surfaces. As a result of exposure to BPA, these aggressive breast cancer cells grew faster and were less likely to die when treated with common anti-cancer drugs. A response of this nature could complicate treatment of this devastating disease.
If you have been diagnosed with cancer and decide to pursue a natural or integrative protocol, traditional insurance policies may not cover the cost of treatments. In this case, there are options to help ensure that everyday financial responsibilities do not become overwhelming.
Leslie R. Schover, Ph.D., founder of the online resource Will2Love which helps cancer survivors in areas of parenthood and sexual wellness, spoke about the effects aromatase inhibitors (AIs) can have on the sex lives of breast cancer patients.
Kelly Turner studies cancer patients who have been told they had only months to live, that there was nothing more that could be done, and yet are walking around cancer-free years later. She calls these cases radical remissions — instead of spontaneous remissions, as they are more commonly referred to — because what she has learned from analyzing more than 1,000 (out of an estimated 100,000) of these cases is that there are common threads among the behaviors of the people who have radical remissions.
The exciting new science of epigenetics has shown that environmental factors can affect our genetic risk of cancer and other diseases. The good news is that epigenetic changes can go both ways—not only can environmental factors cause cancer; they can also prevent it and potentially cure it. Although the science of epigenetics is in its early stages, we now know that we have more control over cancer and other diseases than we thought we did.
Maybe it is because I am getting older? Whatever it is, more research needs to be done. It is really frustrating and embarrassing, too. But I can say this: Things have started to get better. It has been months since I had a major memory obstacle. However, I still find some trouble getting my words out. And for those who are still battling chemo brain, please know it will get better. I know it is frustrating. Hopefully, in time it will go away. But I honestly think I always will have some of it left in me.
Some women are more prone to getting breast cancer than others. Knowing your risk may prove empowering, especially at a time when prevention efforts are growing in both importance and availability. With today’s focus on preventing cancer when possible, some medical leaders are designing programs specifically to identify high-risk women and help them avoid becoming the one in eight women who will be diagnosed with breast cancer in her lifetime.
Male breast cancer (MBC) is a rare and poorly understood disease, but recent molecular studies have revealed fundamental differences from female breast cancer that could help guide treatment strategies toward a more tailored approach